Abstract
Importance SARS-CoV-2 causes multiple immune-related reactions at various stages of the disease, and the wide variety of cutaneous presentations has delayed linking these to the virus. Previous studies had attempted to look at the prevalence and timing of COVID-19 rashes but were mostly based on hospitalized severe cases with limited follow up.
Objective To assess the diagnostic value of new skin rashes in SARS-CoV-2 infection.
Design Observational study including data collected longitudinally via the COVID Symptom Study app between May 7th and June 22nd, 2020, as well as data from an independent online survey on skin-related symptoms.
Setting Community-based
Participants Volunteer sample of 336,847 UK users of the COVID Symptom Study app and 11,546 surveyees, aged 1 to 90 years old.
Exposure Users self-reporting a positive or negative SARS-CoV-2 swab test result, untested symptomatic users, and survey respondents.
Main Outcome(s) and Measure(s) the diagnostic value of new skin rashes in SARS-CoV-2 infection, and observation on their duration and timing in relation to other COVID-19 symptoms
Results In the app data, 8.8% of the swab positive cases (N=2,021) reported either a body rash or an acral rash, compared to 5.4% of those with a negative swab test (N=25,136). Together, these two cutaneous presentations showed an odds ratio (OR) of 1.67 (95% confidence interval [CI]: 1.42-1.97) for being swab positive. Skin rashes were also predictive in the larger untested group of symptomatic app users (N=54,652), as 8.2% of those who had reported at least one classic COVID-19 symptom, i.e., fever, persistent cough, and/or anosmia, also reported a rash. Data from the independent online survey showed that in 17% of swab positive cases, the rash was the initial presentation. Furthermore, in 21%, the rash was the only clinical sign.
Conclusions and Relevance Skin rashes cluster with other COVID-19 symptoms, are predictive of a positive swab test and occur in a significant number of cases, either alone or before other symptoms. Recognising rashes is important for the early detection of COVID-19 cases. To help healthcare professionals in this task we have established a large library of high-quality manually curated photos, available at: https://covidskinsigns.com
Question What is the diagnostiv value of the cutaneous manifestation of SARS-CoV-2 infection?
Findings We confirmed, in a community-based setting, that the presence of a rash is predictive of SARS-CoV-2 infection, and provided a large library of cutaneous manifestation photos to help healthcare professionals in diagnosing COVID-19.
Meaning Skin rashes should be considered as part of the clinical presentation of COVID-19 to aid earlier diagnosis and curb the spread of the infection.
Competing Interest Statement
AB and JW are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. JK is an honorary consultant for Zoe Global Ltd. The other authors have no conflict of interest to declare.
Funding Statement
Zoe Global Limited provided in kind support for all aspects of building, running, and supporting the app and service to all users worldwide. Investigators received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with King's College London. This work was also supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the King's College London Research Ethics Committee REMAS ID 18210, review reference LRS-19/20-18210 and all subscribers provided informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† These authors jointly supervised this work
Data Availability
Data collected in the app are being shared with other health researchers through the NHS-funded Health Data Research UK (HDRUK)/SAIL consortium, housed in the UK Secure e-Research Platform (UKSeRP) in Swansea. Anonymized data collected by the symptom tracker app can be shared with researchers who provide a methodologically sound proposal via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). Data updates can be found at https://covid.joinzoe.com. The app code is publicly available from https://github.com/zoe/covid-tracker-react-native. The data screening script is publicly available from https://github.com/KCL-BMEIS/zoe-data-prep.
https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6
